Nektar Therapeutics (NKTR) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $66.69 +1.51%
Revenue Growth %: -7.1%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
General and administrative: 10.25M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.53, $0.14 better than the analyst estimate of $0.39. Revenue for the quarter came in at $132.9 million versus the consensus estimate of $123.2 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
